Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.05B P/E - EPS this Y -277.30% Ern Qtrly Grth -
Income -468.57M Forward P/E -1.43 EPS next Y 47.30% 50D Avg Chg 2.00%
Sales 241.47M PEG - EPS past 5Y - 200D Avg Chg 43.00%
Dividend N/A Price/Book 10.65 EPS next 5Y - 52W High Chg -13.00%
Recommedations 3.00 Quick Ratio 1.36 Shares Outstanding 150.65M 52W Low Chg 138.00%
Insider Own - ROA -13.84% Shares Float 225.61K Beta 0.66
Inst Own 7.44% ROE - Shares Shorted/Prior 262.05K/292.87K Price 7.56
Gross Margin 75.09% Profit Margin -190.61% Avg. Volume 205,520 Target Price 14.16
Oper. Margin -960.15% Earnings Date Aug 7 Volume 243,218 Change -1.69%
About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.

MorphoSys AG News
07/12/24 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
06/20/24 MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
06/20/24 Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
05/23/24 Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
05/17/24 Erasca restructures; Novartis moves to complete MorphoSys deal
05/10/24 MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
04/29/24 MorphoSys AG Reports First Quarter 2024 Financial Results
04/24/24 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
04/12/24 Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
04/11/24 Novartis (NVS) to Undertake Job Cuts in Development Department
04/11/24 MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
04/11/24 UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys
03/22/24 MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
03/15/24 MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript
03/13/24 MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
03/11/24 The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
03/08/24 5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
03:15 PM Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
03/04/24 MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?
MOR Chatroom

User Image JB_Research Posted - 07/30/24

$HOOK replaced both CEO and CFO last week! "Dr. Peters and Ms. Coelho are the right leaders for this next stage ....with the aim of ensuring value for shareholders." "Dr. Peters is a seasoned executive with deep experience in bringing new therapies to patients and most recently served as Chief Research and Development Officer at MorphoSys $MOR, while Ms. Coelho is a proven CFO with significant expertise in business development, finance, and M&A who most recently served as CFO for Gamida Cell $GMDA" bye Jorn... https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-announces-leadership-changes-intensify-focus-hb

User Image seforim Posted - 07/18/24

$KPTI $NVS $MOR $INCY This is a BIG deal for Karyopharm 🤞🏼 https://x.com/kinatsofrim/status/1813957367278760325

User Image seforim Posted - 07/18/24

$KPTI $NVS $INCY $MOR https://x.com/kinatsofrim/status/1813885761424380140

User Image briefingcom Posted - 07/12/24

$MOR: MorphoSys reports Merger squeeze-out cash compensation determined at EUR 68.00 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240712083929MOR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image lecorb Posted - 2 months ago

$MGOL SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates $ALLG, $MOR, $BEST, MGOL on Behalf of Shareholders. NEW YORK, June 29, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: https://halpersadeh.com/actions/mgo-global-inc

User Image DonCorleone77 Posted - 06/20/24

$MOR $NVS MorphoSys and Novartis sign delisting agreement MorphoSys (MOR) has entered into a delisting agreement with Novartis (NVS) following the successful closing of the acquisition of MorphoSys by Novartis in May. Novartis BidCo Germany AG also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders EUR68.00 per share in cash. As of June 20, Novartis holds approximately 91.04% of the total MorphoSys share capital. As a result, Novartis is the majority shareholder of MorphoSys, making MorphoSys a Novartis company. Novartis intends to launch a public delisting purchase offer for all outstanding MorphoSys no-par value bearer shares. Novartis will offer MorphoSys shareholders EUR 68.00 per share in cash. The Delisting Offer document is expected to be published by Novartis in early July. Once the Delisting Offer document is published by Novartis, a four-week offer period for MorphoSys shareholders to tender their shares will commence. After the delisting becomes effective, MorphoSys shares will no longer be traded on the regulated market of the Frankfurt Stock Exchange or on NASDAQ. Both the delisting from the Frankfurt Stock Exchange and the delisting from NASDAQ are expected to take place in Q3. Novartis also informed MorphoSys of their intention to merge MorphoSys into Novartis. Given Novartis holds approximately 91.04% of the total MorphoSys share capital, Novartis is able to facilitate a squeeze-out of MorphoSys' minority shareholders in connection with such a merger. Novartis will therefore seek the transfer of MorphoSys' minority shareholders' shares to Novartis against an adequate cash compensation. The amount of the cash compensation has not yet been determined. It is planned that the necessary shareholders' resolution on the merger squeeze-out will be adopted at the MorphoSys Annual General Meeting expected to take place in August.

User Image fassrupe Posted - 06/20/24

$MOR NOVATRIS IS TAKING OVER MOR €68.00 PER SHARE https://www.morphosys.com/en/investors/Novartis-TakeoverOffer https://www.stocktitan.net/news/MOR/morpho-sys-and-novartis-sign-delisting-agreement-and-intend-to-i5i6fg65vvpa.html $TPST $GME $VXRT

User Image fassrupe Posted - 06/20/24

$MOR NOVATRIS IS TAKING OVER $MOR €68.00 PER SHARE https://www.morphosys.com/en/investors/Novartis-TakeoverOffer https://www.stocktitan.net/news/MOR/morpho-sys-and-novartis-sign-delisting-agreement-and-intend-to-i5i6fg65vvpa.html $TPST $DJT $VXRT $MBIO

User Image fassrupe Posted - 06/20/24

$MOR https://www.stocktitan.net/news/MOR/morpho-sys-and-novartis-sign-delisting-agreement-and-intend-to-i5i6fg65vvpa.html

User Image seforim Posted - 06/14/24

$KPTI $NVS $MOR $INCY https://x.com/kinatsofrim/status/1801442006171898301

User Image Hbogati Posted - 3 months ago

$NVS $MOR here we go again, Fudstein doing a last minute bashing! What can he do, friends need to close their short positions urgently. Price is above the buyout offer for days now, Novartis getting extra money from Hi bio buyout. Things are getting desperate, losses probably huge. https://www.statnews.com/2024/06/04/novartis-morphosys-myelofibrosis-pelabresib/

User Image Hbogati Posted - 3 months ago

$MOR here we go again, Fudstein doing a last minute bashing! What can he do, friends need to close their short positions urgently. Price is above the buyout offer for days now, Novartis getting extra money from Hi bio buyout. Things are getting desperate, losses probably huge. https://www.statnews.com/2024/06/04/novartis-morphosys-myelofibrosis-pelabresib/

User Image seforim Posted - 3 months ago

$MOR $NVS trouble in paradise? $KPTI $INCY https://x.com/kinatsofrim/status/1797925580358443275

User Image Okadarlan Posted - 3 months ago

$MOR waiting for the final.. either i get out.. and lose 30 k, or this drops and i get my money back who knows.

User Image seforim Posted - 05/24/24

$MOR $NVS $INCY $KPTI https://x.com/kinatsofrim/status/1794032638170460634

User Image Hbogati Posted - 05/22/24

$MOR so NVS gets also 15% of 1.15 B from this: https://www.morphosys.com/en/news/morphosys-and-hibio-enter-equity-participation-and-license-agreements-felzartamab-and-mor210

User Image waltershowalter Posted - 05/16/24

$MOR I accepted the tender offer last Friday. Now the market price is over $19 US? Wonder if I’ll get less than current market price, which I thought would be in the 18s. Guess so? And not understanding the surge either.

User Image DonCorleone77 Posted - 05/16/24

$MOR $NVS Novartis meets all tender offer conditions to acquire MorphoSys Novartis BidCo AG, an indirect wholly owned subsidiary of Novartis AG (NVS), announced the result of its voluntary public takeover offer for the shares of MorphoSys AG (MOR), including all shares represented by MorphoSys American Depositary Shares, or "ADS.". As of the expiry of the acceptance period at 24:00 hours CEST on May 13, the offer has been accepted by approximately 79.6% of the total share capital of MorphoSys, including purchases by Novartis BidCo AG outside the offer for approximately 11.6% of the share capital. All conditions of the offer, including the minimum acceptance threshold of 65%, were fulfilled by the end of the acceptance period. The settlement of the shares tendered during the initial acceptance period is scheduled for May 23. "With all offer conditions fulfilled, Novartis can now begin the necessary steps to progress the integration of MorphoSys, including full access to pelabresib (CPI-0610), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis. The integration also allows full access to tulmimetostat (CPI-0209), an early-stage investigational dual inhibitor of EZH1 and EZH2 currently being tested in patients with solid tumors or lymphomas, as well as a broad portfolio of partnered assets, some of which are in partnership with Novartis, including ianalumab (VAY736). In the context of the integration Novartis continues to progress the workstreams for implementation of both a delisting of MorphoSys and a domination and profit and loss transfer agreement with MorphoSys," the company stated.

User Image Mergerbrief Posted - 05/13/24

$MOR $NVS - Tender Offer Expires 5pm MergerBrief.com

User Image seforim Posted - 05/10/24

$INCY $NVS $MOR $KPTI https://x.com/kinatsofrim/status/1788958398278430738

User Image seforim Posted - 4 months ago

$NVS $MOR $ABBV $INCY $KPTI Vote. Poll redo, will Novartis back out of Morphosys acquisition? https://x.com/kinatsofrim/status/1787532464623071341

User Image AlexPEC Posted - 4 months ago

$MOR https://www.statnews.com/2024/05/02/novartis-morphosys-pelabresib-alzheimers-annovis-bio/

User Image seforim Posted - 4 months ago

$KPTI $ABBV $NVS $MOR $INCY https://x.com/kinatsofrim/status/1786504273854918963

User Image seforim Posted - 4 months ago

$KPTI $NVS $MOR $INCY https://x.com/kinatsofrim/status/1786454412044488965

User Image mich1282 Posted - 4 months ago

$ATNM within this article there is an interesting podcast with AF and other Stat members. The article talks about NVS acquisition of $Mor and some of the potential issues they have experienced on the drug arm. Essentially, some of the MF patients are developing secondary malignancies - AML https://www.statnews.com/2024/05/02/readout-loud-podcast-mount-sinai-brain-research-obesity-drugs-novartis/

User Image Okadarlan Posted - 4 months ago

$MOR So my unrealized lose on this is still not done, haha i am waiting for the crash when the deal does not go through @Racehorsetrainer

User Image Okadarlan Posted - 4 months ago

$MOR Still a unrealized lose tho, i am waiting for the deal to blown off, and i think it will be.

User Image mich1282 Posted - 04/30/24

@saerdna1968a @jster Conway they let go of this for ~$600M. This will rise over the next year or it will decline and leap when data comes. I’m biased as a bull, but way too much value in Endo and MF. $mor sold for 2.9B - they don’t have Endo and their product covers 30% of the MF market compared to our 70%. We need mgmt to execute and good data.

User Image epsguid Posted - 04/29/24

$MOR reported a loss of $2.24, consensus was ($0.51) via @eWhispers #epsmiss http://eps.sh/d/mor

User Image Stock_Titan Posted - 04/29/24

$MOR MorphoSys AG Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/MOR/morpho-sys-ag-reports-first-quarter-2024-financial-n1kjgbvylgfr.html

Analyst Ratings
Wells Fargo Equal-Weight Mar 14, 24
Wells Fargo Overweight Feb 5, 24
Morgan Stanley Equal-Weight Jan 19, 24
Morgan Stanley Equal-Weight Jan 16, 24
Wells Fargo Overweight Dec 15, 23
JP Morgan Overweight Dec 5, 23
Goldman Sachs Neutral Nov 22, 23
JMP Securities Market Outperform Nov 21, 23
Morgan Stanley Overweight Oct 13, 23